COMMUNIQUÉS West-GlobeNewswire

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
31/03/2025
Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic [...]
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
31/03/2025
Pre-Clinical Study in Collaboration with Netherlands Cancer Institute is in addition to LIXTE’s Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- LIXTE [...]
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
31/03/2025
SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
LB Pharmaceuticals Presents New Data from Phase 2 Clinical Trial of LB-102 at the 2025 Annual Congress of the Schizophrenia International Research Society
31/03/2025
Treatment with LB-102 resulted in a positive shift in disease severity as measured by mean change from baseline in Clinical Global Impression of Severity (CGI-S) scores Phase 3 clinical trial of LB-102 in acute [...]
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
31/03/2025
ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI Inhibition DOYLESTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- [...]
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
31/03/2025
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect [...]
Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System
31/03/2025
Integration of Arabic opens opportunities in the Middle East and supports Company’s strategic global expansion goals NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or [...]
Opus Genetics Announces Financial Results for Full Year 2024
31/03/2025
Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases Strong cash position with $21.5 million financing to supplement $30.3 million [...]
Transactions in connection with share buy-back program
31/03/2025
Company Announcement COPENHAGEN, Denmark; March 31, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce [...]
Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI
31/03/2025
AGOURA HILLS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic,” the “Company,” or “We”), a leader in RNA-based therapeutics, today announced the publication of its latest [...]
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
31/03/2025
LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung [...]
LifeMD to Participate in the 24th Annual Needham Virtual Healthcare Conference
31/03/2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that management will be participating in the 24 th Annual Needham Virtual [...]
FluidForm Bio™ Announces Participation in Venture Summit West
31/03/2025
WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced that Mike Graffeo, CEO and co-founder, will deliver a company [...]
CorVista Health Presents New Data on Non-Invasive Point of Care Testing for Pulmonary Capillary Wedge Pressure (PCWP) Elevation Using Machine Learning
31/03/2025
New data show the machine learning algorithms may be used to detect PCWP elevation, aiding in assessment of heart failure with preserved ejection fraction (HFpEF) and pulmonary hypertension (PH) subtypes Data was [...]
BetterLife Pharma Appoints New Director
31/03/2025
VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) ( CSE: BETR / OTCQB : BETRF / FRA: NPAU ), an emerging biotech company, is pleased to announce it [...]
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
31/03/2025
CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to [...]
Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site
31/03/2025
As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technology GARDEN CITY, N [...]
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
31/03/2025
Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, March 31, 2025 (GLOBE [...]
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
31/03/2025
NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business [...]

Pages